BlackRock, Inc. 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 7:44 pm Purchase | 2025-06-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 4,917,501 5.500% | 2,247,760 (+84.19%) | Filing |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 2,669,741 3.900% | -1,332,593 (-33.30%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 4,002,334 5.900% | 385,408 (+10.66%) | Filing |
| 2023-02-13 2:27 pm Purchase | 2022-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 3,616,926 5.500% | 3,616,926 (New Position) | Filing |